Drug profile

The FDA adverse-event record for Iverheart

21 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Iverheart. See the species affected, top reactions, and outcomes below.

21
adverse-event reports
4.8%
death-coded share
Dog
most-reported species
11
Lack of efficacy (endoparasite) - heartworm - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
21
Total Reports
1
Deaths Reported
4.8%
Death Rate

Active Ingredients

Iverheart

Administration Routes

OralUnknownSubcutaneousOther

Species Affected

Dog 21

Most Affected Breeds

Griffon - Brussels 5
Terrier - Bull - American Pit 4
Retriever - Labrador 2
Crossbred Canine/dog 2
Collie - Border 1
Shar Pei 1
Terrier - Jack Russell 1
Pointing Dog - Hungarian Short-haired (Vizsla) 1
Shepherd (unspecified) 1
Terrier (unspecified) 1

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 11
Vomiting 5
INEFFECTIVE, HEARTWORM LARVAE 1
Weight loss 1
Lethargy (see also Central nervous system depression in 'Neurological') 1
Hypoadrenocorticism 1
Nasal cavity disorder NOS 1
Death by euthanasia 1
Skin lump 1
Abnormal radiograph finding 1
Pain NOS 1
Lethargy (see also Central nervous system depression in Neurological) 1

Outcome Breakdown

Ongoing
11 (52.4%)
Recovered/Normal
6 (28.6%)
Outcome Unknown
3 (14.3%)
Euthanized
1 (4.8%)

Iverheart Adverse Event Insights

21 reports name Iverheart; 1 recorded a death outcome (4.8% of reported events, not a population-level mortality rate). Active ingredient: Iverheart. Administration routes: Oral, Unknown, Subcutaneous, Other.

By species: Dog (21 reports). By breed: Griffon - Brussels (5), Terrier - Bull - American Pit (4), Retriever - Labrador (2).

Leading clinical signs: Lack of efficacy (endoparasite) - heartworm (11), Vomiting (5), INEFFECTIVE, HEARTWORM LARVAE (1), Weight loss (1). Outcome, 21 coded reports: Ongoing leads at 52.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.